Promising new drug target for inflammatory lung diseases

September 6th, 2012
Promising new drug target for inflammatory lung diseases Enlarge
Journal of Interferon & Cytokine Research © Mary Ann Liebert, Inc., publishers
The naturally occurring cytokine interleukin-18, or IL-18, plays a key role in inflammation and has been implicated in serious inflammatory diseases for which the prognosis is poor and there are currently limited treatment options. Therapies targeting IL-18 could prove effective against inflammatory diseases of the lung including bronchial asthma and chronic obstructive pulmonary disease (COPD), as described in a review article published in Journal of Interferon & Cytokine Research (http://www.liebertpub.com/jir), a peer-reviewed publication from Mary Ann Liebert, Inc., publishers.

Tomotaka Kawayama and coauthors from Kurume University School of Medicine, Fukuoka, Japan, University of Ryukyus, Okinawa, Japan, and Frederick National Laboratory for Cancer Research, Frederick, MD, review the growing evidence to support the important role IL-18 has in inflammation and how it may help to initiate and worsen inflammatory disorders such as arthritis, dermatitis and inflammatory diseases of the bowel and immune system. In the article "Interleukin-18 in Pulmonary Inflammatory Diseases" (http://online.liebertpub.com/doi/full/10.1089/jir.2012.0029) they describe the potential benefits of therapies aimed at blocking the activity of IL-18 to treat inflammatory lung disease.

"This review provides an interesting and thorough summary of the biology and potential application of IL-18 in the setting of inflammatory pulmonary disease," says Co-Editor-in-Chief Thomas A. Hamilton, PhD, Chairman, Department of Immunology, Cleveland Clinic Foundation.

More information:
The article is available free online at the Journal of Interferon & Cytokine Research website.

Provided by Mary Ann Liebert, Inc

This Phys.org Science News Wire page contains a press release issued by an organization mentioned above and is provided to you “as is” with little or no review from Phys.Org staff.

More news stories

Panic over MERS virus fades in Saudi

People in Saudi Arabia's Eastern Province have again started greeting friends with the traditional kiss on the cheek, and face masks in public are becoming rarer, as panic subsides over the outbreak of a deadly respiratory ...

French firemen test hypnosis to help victims

"Look me straight in the eye. Your mind is emptying, your body is relaxing," says the fireman, using the calming words of hypnosis to help a trauma victim—a technique being pioneered by fire crews in the eastern French ...

Dusty surprise around giant black hole

(Phys.org) —ESO's Very Large Telescope Interferometer has gathered the most detailed observations ever of the dust around the huge black hole at the centre of an active galaxy. Rather than finding all of ...

Taiwan's Hon Hai to hire 3,000 after Mozilla tie-up

Taiwan's Hon Hai Precision said Thursday it aims to hire up to 3,000 new employees to develop devices and software for Mozilla's Firefox operating system as it seeks to diversify from its core manufacturing services.

How do bees make honey? It's not just bee barf

(Phys.org) —Last weekend, my daughter asked me how bees made honey, and I realized that I didn't know the answer. How do bees make honey? I did some homework, and can now explain it to her – and to you.